STOCK TITAN

Lisata Therapeutics, Inc. - $LSTA STOCK NEWS

Welcome to our dedicated page for Lisata Therapeutics news (Ticker: $LSTA), a resource for investors and traders seeking the latest updates and insights on Lisata Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lisata Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lisata Therapeutics's position in the market.

Rhea-AI Summary
Lisata Therapeutics announces treatment of first patient in head and neck squamous cell carcinoma cohort of BOLSTER trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.51%
Tags
none
-
Rhea-AI Summary
Lisata Therapeutics announces positive outcome of interim futility analysis for ASCEND trial, study to continue as planned
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.91%
Tags
-
Rhea-AI Summary
Lisata Therapeutics CEO to present at upcoming conferences in September
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Lisata Therapeutics receives Orphan Drug Designation for LSTA1 in the treatment of malignant glioma
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.3%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.49%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
Lisata Therapeutics, Inc.

Nasdaq:LSTA

LSTA Rankings

LSTA Stock Data

23.67M
6.75M
19%
8.93%
0.2%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
BASKING RIDGE

About LSTA

caladrius biosciences, inc., a clinical-stage biopharmaceutical company, develops cellular therapeutic product candidates to address diseases and conditions caused by ischemia. its product candidates include developmental treatments for cardiovascular diseases, such as clbs12 for the treatment of critical limb ischemia; clbs16, which is in phase ii clinical trial for the treatment of coronary microvascular dysfunction; clbs14, a regenerative medicine advanced therapy for treating no-option refractory disabling angina. the company was formerly known as neostem, inc. and changed its name to caladrius biosciences, inc. in june 2015. caladrius biosciences, inc. was founded in 1980 and is headquartered in basking ridge, new jersey.